Endogenous androgens and risk of epithelial ovarian cancer: Results from the European Prospective Investigation into Cancer and Nutrition (EPIC)

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 1, 2007, Pages 23-29

  Rinaldi, Sabina ^a   Dossus, Laure ^a,b   Lukanova, Annekatrin ^b,c   Peeters, Petra H M ^d   Allen, Naomi E ^e   Key, Timothy ^e   Bingham, Sheila ^f   Khaw, Kay Tee ^g   Trichopoulos, Dimitrios ^h   Trichopoulou, Antonia ^h   Oikonomou, Eleni ^h   Pera, Guillem ⁱ   Larrañaga, Nerea ^j   Martinez Garcia, Carmen ^k   Ardanaz, Eva ^l   Quirós, J Ramón ^m   Tormo, María José ⁿ   Tjønneland, Anne ^o   Olsen, Anja ^o   Overvad, Kim ^p   Chang Claude, Jenny ^b   Linseisen, Jakob ^b   Schulz, Mandy ^q   Boeing, Heiner ^q   Van Gils, Carla H ^d   Bueno De Mesquita, Bas H ^r   Pala, Valeria ^s   Palli, Domenico ^t   Panico, Salvatore ^u   Tumino, Rosario ^v   Vineis, Paolo ^w   Clavel Chapelon, Françoise ^x   Mesrine, Sylvie ^x   Boutron Ruault, Marie Christine ^x   Lundin, Eva ^y   Ågren, Åsa ^y   Berglund, Göran ^z   Manjer, Jonas ^z   Kumle, Merethe ^aa   Lund, Eiliv ^aa   Slimani, Nadia ^a   Saracci, Rodolfo ^a   Riboli, Elio ^w   Kaaks, Rudolf ^a,b   more..

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g ADDENBROOKE S HOSPITAL   (United Kingdom)

^h UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

ⁱ CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^j Basque Government   (Spain)

^k ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^l INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^m Public Health and Health Planning Directorate   (Spain)

ⁿ Consejería de Sanida ^*  (Spain)

^o INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^p AALBORG UNIVERSITY HOSPITAL   (Denmark)

^q GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^r NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^s NATIONAL CANCER INSTITUTE   (Italy)

^t Scientific Institute of Tuscany   (Italy)

^u UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^v CIVILE M P AREZZO HOSPITAL   (Italy)

^w IMPERIAL COLLEGE LONDON   (United Kingdom)

^x INSERM   (France)

^y UMEÅ UNIVERSITY   (Sweden)

^z LUND UNIVERSITY HOSPITAL   (Sweden)

^aa UNIVERSITY OF TROMSØ   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RISK; CONTROLLED STUDY; EUROPE; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; NUTRITIONAL ASSESSMENT; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL;

ADULT; AGED; CARCINOMA; CASE-CONTROL STUDIES; DEHYDROEPIANDROSTERONE SULFATE; EUROPE; FEMALE; HUMANS; MIDDLE AGED; NUTRITIONAL STATUS; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 33846577457     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0755     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev 2005;14:98-107.
3. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90:1774-86.
4. Fathalla MF. Incessant ovulation-a factor in ovarian neoplasia? Lancet 1971;2:163.
5. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999;91:1459-67.
6. Cramer DW, Hutchison GB, Welch WR, et al. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst 1983;71:711-6.
7. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983;71:717-21.
8. Godwin AK, Perez RP, Johnson SW, et al. Growth regulation of ovarian cancer. Hematol Oncol Clin North Am 1992;6:829-41.
9. Sawada M, Terada N, Wada A, et al. Estrogen- and androgen-responsive growth of human ovarian adenocarcinoma heterotransplanted into nude mice. Int J Cancer 1990;45:359-63.
10. Beamer WG, Shultz KL, Tennent BJ. Induction of ovarian granulosa cell tumors in SWXJ-9 mice with dehydroepiandrosterone. Cancer Res 1988;48:2788-92.
11. Tennent BJ, Shultz KL, Beamer WG. Genetic susceptibility for C19 androgen induction of ovarian granulosa cell tumorigenesis in SWXJ strains of mice. Cancer Res 1993;53:1059-63.
12. Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 1995;274:1926-30.
13. Lukanova A, Lundin E, Akhmedkhanov A, et al. Circulating levels of sex steroid hormones and risk of ovarian cancer. Int J Cancer 2003;104:636-42.
14. Riboli E, Hunt KJ, Slimani, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113-24.
15. Bingham S, Riboli E. Diet and cancer-the European Prospective Investigation into Cancer and Nutrition. Nat Rev Cancer 2004;4:206-15.
16. Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005;97:755-65.
17. Rinaldi S, Dechaud H, Biessy C, et al. Reliability and validity of commercially available, direct radioimmunoassays for measurement of blood androgens and estrogens in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2001;10:757-65.
18. Rinaldi S, Geay A, Dechaud H, et al. Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol Biomarkers Prev 2002;11:1065-71.
19. Belgorosky A, Escobar ME, Rivarola MA. Validity of the calculation of non-sex hormone-binding globulin-bound estradiol from total testosterone, total estradiol, and sex hormone-binding globulin concentrations in human serum. J Steroid Biochem 1987;28:429-32.
20. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperature. J Steroid Biochem 1982;16:801-10.
21. Niwa Y, Yatsuya H, Tamakoshi K, et al. Relationship between body mass index and the risk of ovarian cancer in the Japanese population: findings from the Japanese Collaborate Cohort (JACC) study. J Obstet Gynaecol Res 2005;31:452-8.
22. Lukanova A, Toniolo P, Lundin E, et al. Body mass index in relation to ovarian cancer: a multi-centre nested case-control study. Int J Cancer 2002;99:603-8.
23. Hoyo C, Berchuck A, Halabi S, et al. Anthropometric measurements and epithelial ovarian cancer risk in African-American and White women. Cancer Causes Control 2005;16:955-63.
24. Zhang M, Xie X, Holman CD. Body weight and body mass index and ovarian cancer risk: a case-control study in China. Gynecol Oncol 2005;98:228-34.
25. Engeland A, Tretli S, Bjorge T. Height, body mass index, and ovarian cancer: a follow-up of 1.1 million Norwegian women. J Natl Cancer Inst 2003;95:1244-8.
26. Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003;24:152-82.